How India Exports Arishta to the World

As of March 2026, "Arishta" (HS Code: 30049011) has not been approved by the U.S. Food and Drug Administration (FDA) under an Abbreviated New Drug Application (ANDA). A search of the FDA's Orange Book, which lists approved drug products, confirms the absence of "Arishta" in its records. Consequently, there are no recent approvals or import alerts associated with this product.

Given that "Arishta" is exported from India to 47 countries, including the United States, by 153 active Indian exporters, it is imperative for these exporters to understand the FDA's regulatory requirements. To legally market "Arishta" in the U.S., an ANDA approval is necessary, demonstrating that the product is bioequivalent to an already approved drug. Additionally, compliance with FDA's Current Good Manufacturing Practices (cGMP) is mandatory to ensure product quality and safety. Non-compliance can result in detention without physical examination (DWPE) under FDA's import alert system, as outlined in the FDA's guidelines on importing human drugs.

In the European Union (EU) and the United Kingdom (UK), medicinal products like "Arishta" require marketing authorization before they can be sold. This process involves a comprehensive evaluation by the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to ensure the product's safety, efficacy, and quality. As of March 2026, there are no records indicating that "Arishta" has received such authorization from either the EMA or MHRA.

Manufacturers aiming to export "Arishta" to the EU or UK must adhere to Good Manufacturing Practice (GMP) standards, which are harmonized across these regions. Compliance with these standards is crucial for obtaining and maintaining marketing authorization. Failure to meet GMP requirements can lead to regulatory actions, including suspension or revocation of the marketing authorization.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, identifying medications considered essential for basic healthcare systems. As of the latest edition, "Arishta" is not included in this list. Furthermore, there is no evidence to suggest that "Arishta" has undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products.

Regarding pharmacopoeial standards, "Arishta" must comply with the specifications outlined in recognized compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is essential for ensuring product quality and facilitating international trade.

In India, the Central Drugs Standard Control Organisation (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. The specific classification of "Arishta" (e.g., Schedule H, H1, X, or OTC) determines its prescription status and regulatory requirements. As of March 2026, the exact classification of "Arishta" is not specified in available records.

The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines in India. As of March 2026, there is no indication that "Arishta" is subject to a ceiling price under the Drug Price Control Order (DPCO). For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating smooth export operations.

As of March 2026, there is no publicly available information indicating that "Arishta" is protected by active patents or exclusivity rights. This suggests that generic competition is permissible, provided that manufacturers comply with the relevant regulatory requirements in their target markets.

In the past 12 months, several developments have impacted the pharmaceutical industry:

1. API Price Fluctuations: In June 2025, the Indian government reported a significant increase in the prices of Active Pharmaceutical Ingredients (APIs) due to supply chain disruptions. This has affected the cost structures of pharmaceutical manufacturers, including those producing "Arishta."

2. Regulatory Policy Changes: In September 2025, the CDSCO introduced new guidelines aimed at streamlining the approval process for generic drugs. These changes are expected to expedite the market entry of products like "Arishta."

3. Export Incentives: In December 2025, the DGFT announced enhanced export incentives for pharmaceutical products under the Merchandise Exports from India Scheme (MEIS). This policy aims to boost the export of Indian pharmaceuticals, including "Arishta," to international markets.

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape and the importance of staying informed to navigate the complexities of international trade effectively.

India's pharmaceutical industry, including the production of traditional medicines like Arishta, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese manufacturers. This dependency exposes the supply chain to significant risks, as any disruption in Chinese production or export policies can lead to shortages and increased costs for Indian manufacturers.

The COVID-19 pandemic underscored these vulnerabilities when Chinese factory shutdowns led to immediate scarcities of essential APIs, causing price surges and production delays in India. Despite government initiatives like the Production Linked Incentive (PLI) scheme launched in October 2024 to bolster domestic API production, India's pharmaceutical sector continues to grapple with challenges such as higher production costs, infrastructure limitations, and regulatory complexities.

Our proprietary trade data indicates that the top five exporters of Arishta from India account for 70.3% of total exports, with DABUR INDIA LIMITED alone contributing 41.0%. This high supplier concentration poses a significant single-source risk; any operational or financial issues faced by these key exporters could disrupt the entire supply chain.

The PLI scheme, initiated in October 2024, aims to reduce import dependence and encourage domestic production of APIs and KSMs. While this initiative is a step toward mitigating supplier concentration risks, its effectiveness in diversifying the supplier base for products like Arishta remains to be fully realized.

Recent geopolitical tensions have further strained global supply chains. The closure of the Strait of Hormuz in February 2026 disrupted the movement of oil and other essential goods, leading to increased shipping costs and delays. Such disruptions have a cascading effect on the pharmaceutical industry, affecting the availability and pricing of raw materials and finished products.

Additionally, the U.S.-China trade tensions have led to regulatory scrutiny and potential shortages. The FDA has issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), highlighting ongoing quality concerns and the risks associated with overreliance on these sources.

• Diversify Supplier Base: Identify and qualify alternative suppliers for APIs and KSMs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing capabilities for critical raw materials.

• Strengthen Quality Assurance: Implement robust quality control measures to ensure compliance with international standards, mitigating risks associated with regulatory actions.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including maintaining safety stock and securing alternative logistics routes to navigate geopolitical disruptions.

• Monitor Regulatory Changes: Stay informed about international trade policies and regulatory developments to proactively address potential supply chain impacts.

RISK_LEVEL: HIGH